Dianexin
Alternative Names: Annexin A5 recombinant - Alavita; ASP-8597; DiannexinLatest Information Update: 05 Nov 2023
At a glance
- Originator Alavita Pharmaceuticals
- Developer Astellas Pharma
- Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Antivirals; Biological peptides; Calcium binding proteins; Cardiovascular therapies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators; Phosphatidylserine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 01 Jul 2013 Astellas Pharma terminates phase II/III trial in Reperfusion injury in USA (NCT01442337)
- 04 Feb 2013 Discontinued - Phase-II/III for Reperfusion injury in USA (IV)
- 26 Oct 2012 Astellas Pharma suspends a phase II/III trial in Reperfusion injury (prevention) in USA (NCT01442337)